DNA + RNA Whole Transcriptome Sequencing
29% more patients were identified with a unique clinically actionable fusion matched to a targeted therapy, compared to DNA sequencing alone.1
Solid Tumor and Normal Matched DNA Sequencing
28% reduction in somatic false-positive calls, improving accuracy compared to tumor-only analysis.2
Incidental Germline Findings
7% of patients were found to harbor pathogenic or likely pathogenic germline variants across multiple cancer types and are indicated for confirmatory germline testing, per high risk assessment guidelines.3,4
Concurrent Solid Tumor and Liquid Biopsy Testing
9% of patients had unique actionable variants found in liquid biopsy that were not detected in solid tumor alone.5
Clinical Data Integration
96% of patients matched to a clinical trial when clinical data was combined with Tempus NGS.2
Automatic Conversion Option
In the event of insufficient tumor tissue, convert to liquid biopsy testing for rapid genomic results.
Algorithmic Tests
We provide advanced patient insights without the need for additional tissue.